STOCK TITAN
  1. Home
  2. News
  3. ATRA

Atara Biotherapeutics, Inc - ATRA STOCK NEWS

Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.

Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.

The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:

  • Pinta 745
  • STM 434
  • ATA 842

Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:

  • Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
  • Cytomegalovirus (CMV)-targeted CTLs
  • Wilms Tumor 1 (WT1)-targeted CTLs

These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.

Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.

The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.

Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.

News

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Atara Biotherapeutics, Inc. granted 3,750 restricted stock units to a new employee under the 2018 Inducement Plan. The units vest over four years, subject to continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
News

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Rhea-AI Summary
Atara Biotherapeutics (ATRA) reported positive pre-BLA meeting for tab-cel, expanding into autoimmune diseases. Financially, they received $27 million upfront from Pierre Fabre, potentially $640 million more, with key pipeline readouts funded till 2027. ATA3219 lupus nephritis study planned with initial data in H1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
earnings
-
News

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Rhea-AI Summary
Atara Biotherapeutics, Inc. receives second IND clearance for ATA3219, a CAR T-cell therapy for lupus nephritis. Clinical data expected in 2024 and 2025. The therapy aims to address unmet needs in autoimmune diseases, offering potentially curative off-the-shelf treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial
News

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) announces participation in a cell therapy panel discussion at the Cowen 44th Annual Health Care Conference. Pascal Touchon, President and CEO, to present on March 6, 2024. Webcast details provided for investors and media.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
conferences
-
News

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Rhea-AI Summary
Atara Biotherapeutics submits IND for ATA3219, a novel CAR T-cell therapy targeting lupus nephritis, aiming to revolutionize treatment options for patients with autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Rhea-AI Summary
Atara Biotherapeutics and Pierre Fabre Laboratories announced the publication of pivotal Phase 3 ALLELE study data for tab-cel, an allogeneic T-cell therapy for EBV+ PTLD patients. The study showed a 51.2% objective response rate and a 23.0 month median duration of response. The U.S. BLA submission for tab-cel is on track for Q2 2024. The study met its primary endpoint, and tab-cel was well-tolerated with no reported adverse events. These results highlight the clinical value of tab-cel and its potential to address an urgent unmet medical need for patients with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.01%
Tags
clinical trial
News

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Rhea-AI Summary
Atara Biotherapeutics, Inc. (ATRA) announces a definitive agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock at a purchase price of $0.55 per pre-funded warrant share in a registered direct offering to entities affiliated with an existing institutional investor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.28%
Tags
offering
-
News

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the closing of a partnership expansion with Pierre Fabre Laboratories for the global commercialization of tab-cel. The company's BLA for tab-cel is on track for submission in Q2 2024, following positive new data from the pivotal ALLELE study. Atara also plans to expand its next-gen allogeneic CAR-T portfolio to include autoimmune disease ATA3219. The company's strategic restructuring has extended its cash runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.28%
Tags
conferences
-
News

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at 42nd Annual J.P. Morgan Healthcare Conference, showcasing its T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
News

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Rhea-AI Summary
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced the closing of an expanded global partnership with Pierre Fabre Laboratories for tabelecleucel (tab-cel® or EBVALLOTM). The transaction provides Pierre Fabre Laboratories with the development, manufacturing, and commercialization rights for tab-cel in the United States and all remaining markets. Atara will receive approximately USD 27 million in cash upfront and initial inventory purchase, with the potential to receive up to a total of USD 640 million and significant double-digit tiered royalties on net sales. Atara plans to submit the BLA to the U.S. FDA for tab-cel for the treatment of post-transplant lymphoproliferative disease (PTLD) in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.49%
Tags
partnership

FAQ

What is the current stock price of Atara Biotherapeutics (ATRA)?

The current stock price of Atara Biotherapeutics (ATRA) is $11.47 as of November 22, 2024.

What is the market cap of Atara Biotherapeutics (ATRA)?

The market cap of Atara Biotherapeutics (ATRA) is approximately 64.3M.

What does Atara Biotherapeutics, Inc specialize in?

Atara Biotherapeutics specializes in developing transformative therapies for serious diseases including cancer, kidney disease, and autoimmune disorders.

When was Atara Biotherapeutics founded?

Atara Biotherapeutics was founded in August 2012.

Who is Atara Ciechanover?

Atara Ciechanover is the namesake of the company, who suffered from cancer before passing away in 2012.

What are some of Atara's key product candidates?

Some of Atara's key product candidates include Pinta 745, STM 434, ATA 842, Tab-cel, ATA188, and ATA3219 (CAR T platform).

With which institution is Atara Biotherapeutics collaborating?

Atara Biotherapeutics is collaborating with Memorial Sloan Kettering Cancer Center (MSK).

What types of T-cell therapies is Atara developing?

Atara is developing T-cell therapies targeting Epstein-Barr Virus (EBV)-targeted CTLs, Cytomegalovirus (CMV)-targeted CTLs, and Wilms Tumor 1 (WT1)-targeted CTLs.

What is the mission of Atara Biotherapeutics?

Atara Biotherapeutics aims to provide better treatment options for patients, altering the course of disease progression through innovative therapies.

Where does Atara Biotherapeutics operate?

Atara Biotherapeutics operates in the United States healthcare sector.

What are activin and myostatin in the context of Atara's research?

Activin and myostatin are growth factors that Atara's research has shown can change the course of disease progression.

How does Atara manage its business operations?

Atara manages its business as one operating and reportable segment focusing on developing therapeutics.

Stock ATRA logo
Atara Biotherapeutics, Inc

Nasdaq:ATRA

ATRA Rankings

#4697 Ranked by Market Cap
N/A Ranked by Dividends

ATRA Stock Data

64.28M
4.47M
22.15%
50.83%
11.21%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS